Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Cumberland, Rhode Island Clinical Trials

A listing of Cumberland, Rhode Island clinical trials actively recruiting patient volunteers.

RESULTS

Found (15) clinical trials

Neurocircuitry of Obsessive-Compulsive Disorder: Modulation by Transcranial Direct Current Stimulation

The purpose of this study is to test the effects of non-invasive neuromodulation, transcranial direct current stimulation (tDCS), on brain function in individuals with obsessive-compulsive disorder (OCD). This study is focused on the mechanism(s) by which brain stimulation might change the functioning of regions implicated in OCD, and thereby inform ...

Phase

7.64 miles

Learn More »

Pharmacokinetics of SAR441236

This study will evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of SAR441236, a tri-specific broadly neutralizing antibody against HIV. The study includes two arms. In Arm A, three cohorts of antiretroviral-treated, virologically suppressed participants will be randomized to receive a single intravenous (IV) dose of SAR441236 or placebo on ...

Phase

7.64 miles

Learn More »

A Study of MEDI1191 Alone and in Combination With Durvalumab in Subjects With Advanced Solid Tumors

This is a multicenter, open-label study to evaluate MEDI1191 delivered by intratumoral injection alone and in combination with intravenous durvalumab to subjects with solid tumors. The study has a dose escalation design using mTPI-2 to evaluate a range of doses.

Phase

7.64 miles

Learn More »

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

All subjects who received investigational CAR-T therapy will be included in the analyses and summaries of safety, efficacy, pharmacokinetic, and pharmacodynamic assessments.

Phase

7.7 miles

Learn More »

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

Patients undergo leukapheresis from which peripheral blood mononuclear cells are purified. T cells are activated and then re-engineered to express chimeric antigen receptors (CARs) specific for CEA. Cells are expanded in culture and returned to the patient by intraperitoneal infusion at specific cell doses. One anti-CEA CAR-T dose per patient ...

Phase

7.7 miles

Learn More »

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042 an Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody TSR-042 in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts: dose escalation and cohort expansion. The cohort expansion may include various tumor ...

Phase

8.6 miles

Learn More »

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously treated solid tumors or hematologic malignancies.

Phase

8.6 miles

Learn More »

Oxytocin Stress Craving Opioid Use Disorder

The goal of this research is to evaluate whether oxytocin, a hormone with anti-stress properties, dampens the effects of stress and opioid-associated cues on opioid craving and thus may be an effective adjunctive treatment for OUD. The central hypothesis of this research is that oxytocin will reduce stress-induced opioid craving ...

Phase

8.6 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

9.1 miles

Learn More »

Vincristine Sulfate Liposome Injection (Marqibo ) Bendamustine and Rituximab Phase I Trial in Indolent B-cell Lymphoma

Bendamustine-rituximab is a standard chemotherapy regimen for treatment of many indolent B-cell lymphomas, but most patients experience a recurrence of the lymphoma. Vincristine sulfate has been a traditional component of chemotherapy regimens in non-Hodgkin lymphoma and it is possible that adding it to the bendamustine-rituximab regimen might provide a better ...

Phase

9.1 miles

Learn More »